Top
Leber Hereditary Optic Neuropathy (LHON) caused by mutation of the G11778A gene - Healing Genes
1228
post-template-default,single,single-post,postid-1228,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Leber Hereditary Optic Neuropathy (LHON) caused by mutation of the G11778A gene

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber’s Hereditary Optic Neuropathy (LHON)

An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber’s Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA


Phase 1

DESCRIPTION:

Doctors at the Bascom Palmer Eye Institute of the University of Miami are recruiting participants with a specific type of Leber’s Hereditary Optic Neuropathy (LHON) to help assess the effectiveness of an investigational gene therapy to improve retina structure and function. The mutation targeted by this treatment is the G1178A mitochondrial mutation, where vision has been lost up to one year. The treatment, a genetically modified virus, is designed to impart the functional copy of the gene to cells of the eyes.

Participants will be assigned to receive the investigational drug in both eyes at one of 4 doses. Patients will be followed up to 2 years post treatment.


PATIENT MUST:

  • Be 15 years of age or older
  • Have vision loss of a certain duration of time due to LHON, in at least one eye
  • Not have had previous eye surgery in the eye selected for injection

THE STUDY INVOLVES:

  1. Prescreening to confirm eligibility of the patient to participate
  2. A single intravitreal injection into one or both eyes
  3. Follow up will continue for 1 year.

LOCATIONS AND CONTACTS:
Contact:
JOHN GUY, MD  |  302-326-6036  |  [email protected]

The trial takes place at the Bascom Palmer Eye Institute of the University of Miami. Map.

SPONSOR INFORMATION:
John Guy
National Eye Institute (NEI)

Or go online:
https://clinicaltrials.gov/ct2/show/NCT02161380

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader